Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.58 |
| ▸ | QPCT | Q16769 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.51 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.51 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.51 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10652258 | 0.84 | CYP19A1 (0.69) | CYP19A1QPCTPOLBCYP1A2CYP3A4 | |
| SCHEMBL19368186 | 0.83 | CYP19A1 (0.55) | CYP19A1QPCTPOLBCYP1A2CYP3A4 | |
| SCHEMBL9373635 | 0.81 | CYP19A1 (0.60) | CYP19A1QPCTPOLBCYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL11083585 | 0.80 | CYP19A1 (0.51) | CYP19A1QPCTPOLBCYP1A2CYP3A4 | |
| SCHEMBL3670452 | 0.79 | CYP19A1 (0.58) | CYP19A1QPCTPOLBCYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL11612301 | 0.79 | CYP19A1 (0.58) | CYP19A1QPCTPOLBCYP1A2CYP3A4 | |
| SCHEMBL27203260 | 0.79 | CYP19A1 (0.58) | CYP19A1QPCTPOLBCYP1A2CYP3A4 | |
| SCHEMBL6173273 | 0.79 | CYP19A1 (0.71) | CYP19A1HMOX2 | |
| SCHEMBL6299346 | 0.79 | CYP19A1 (0.71) | CYP19A1HMOX2 | |
| SCHEMBL11698569 | 0.79 | CYP19A1 (0.58) | CYP19A1QPCTPOLBCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113637964-A | Preparation method of anti-oxidation treatment fluid for end face of battery copper foil | 新疆亿日铜箔科技股份有限公司 | 2021-11-12 | — | — | CN | claimed |
| CN-113637964-A | Preparation method of anti-oxidation treatment fluid for end face of battery copper foil | 新疆亿日铜箔科技股份有限公司 | 2021-11-12 | — | — | CN | disclosed |
| CN-113637964-A | Preparation method of anti-oxidation treatment fluid for end face of battery copper foil | 新疆亿日铜箔科技股份有限公司 | 2021-11-12 | — | — | CN | disclosed |
| EP-3233858-B1 | ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20170266167-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
| US-4431815-A | CARDIOTONIC AND ANTISHOCK AGENTS; ANTICOAGULANTS | BURROUGHS WELLCOME CO. (US) | 1984-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266167-A1 | ERK INHIBITORS | MAPK1, MAPK3, MAPK6 | CYP19A1 375/4885QPCT 2363/4885POLB 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.